Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Naishuo Zhu"'
Autor:
Yulai Liang, Huazao Luo, Xue Li, Shuang Liu, Arslan Habib, Baoxiu Liu, Jiansheng Huang, Jingbo Wang, Han Yi, Bo Hu, Liuhai Zheng, Jun Xie, Naishuo Zhu
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundIn recent years, immunotherapy has been emerging as a promising alternative therapeutic method for cancer patients, offering potential benefits. The expression of PD-L1 by tumors can inhibit the T-cell response to the tumor and allow the tu
Externí odkaz:
https://doaj.org/article/6f0a4909d6e940cfad118271e702cf01
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Human Immunodeficiency Virus (HIV-1) is known to establish a persistent latent infection. The use of combination antiretroviral therapy (cART) can effectively reduce the viral load, but the treatment can be costly and may lead to the development of d
Externí odkaz:
https://doaj.org/article/f720b18b92214ea290e698d484e54166
Autor:
Xue Li, Zhenni Wang, Jiansheng Huang, Huazao Luo, Sibo Zhu, Han Yi, Liuhai Zheng, Bo Hu, Lili Yu, Lingzhi Li, Jun Xie, Naishuo Zhu
Publikováno v:
FEBS Open Bio, Vol 9, Iss 6, Pp 1063-1070 (2019)
DNA methylation of promoter regions is often associated with epigenetic silencing of gene expression, and DNA methyltransferase (DNMTs) has been used to suppress gene expression. In order to explore the synergistic roles of two methyltransferase memb
Externí odkaz:
https://doaj.org/article/307406c4329c4ae28dc5714b2026b480
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170313 (2017)
Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects. There is a need to develop new and safe adjuvants, because some existing vaccines have low immun
Externí odkaz:
https://doaj.org/article/c4f27494dcbb4cc388f0701ef3fd2342
Publikováno v:
Frontiers in Immunology; 2023, p1-20, 20p
Publikováno v:
Journal of Cancer
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide. ESCC has a generally poor prognosis and there is a lack of available biomarkers for diagnosis and prognosis. The aim of the study was to identify novel biomarkers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ea1cb7ef7e7e7859342b7a983b7d13
https://doi.org/10.7150/jca.50443
https://doi.org/10.7150/jca.50443
Publikováno v:
Clinical Rheumatology. 39:1111-1120
Anticitrullinated protein/peptide antibodies (ACPAs) have shown valuable effects in the diagnosis of rheumatoid arthritis (RA). Both fibrinogen and vimentin are significant antigens of ACPAs. This study evaluated the diagnostic performance of fibrino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf8e664592d68f9b124a4736b03e1f80
https://doi.org/10.1007/s10067-019-04845-2
https://doi.org/10.1007/s10067-019-04845-2
Publikováno v:
Clinical laboratory. 66(5)
Background This study aimed to evaluate the overall diagnostic value of citrullinated or carbamylated fibrinogen antibodies in patients with rheumatoid arthritis (RA). Methods Serum samples collected from 114 patients with established RA, 143 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765cd38ce7ac512c982b1012e3da92ce
https://pubmed.ncbi.nlm.nih.gov/32390379
https://pubmed.ncbi.nlm.nih.gov/32390379
Publikováno v:
International Immunology. 31:199-209
The induction of a dominant Th2-type response is the main cause of harmful inflammation in respiratory syncytial virus (RSV) vaccine trials. A balanced Th1 versus Th2 immune response is needed for a safe and effective RSV vaccine. In this study, we e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7287ab5b73cac904d9b572d66cbe07e
https://doi.org/10.1093/intimm/dxy078
https://doi.org/10.1093/intimm/dxy078
Publikováno v:
Antiviral Research. 159:95-103
Human respiratory syncytial virus (RSV) is a major paediatric health concern worldwide. The development of an effective and safe vaccine against RSV is urgently needed. As RSV infects via the mucosal surfaces, developing a nasal vaccine may offer pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce139e51027bcc35e4298409afdb0185
https://doi.org/10.1016/j.antiviral.2018.10.001
https://doi.org/10.1016/j.antiviral.2018.10.001